Newport Beach-based Acacia Research Corp. has bolstered its portfolio of medical devices and technology patents with its latest buy.
The company, which licenses patents from its own portfolio and for other companies, announced on Thursday it has acquired the rights to certain patents in the orthopedic sector from an undisclosed company.
The buy highlights its shift to license patents beyond the technology industry and target medical and diagnostic companies.
Acacia has made several acquisitions in the medical sector in recent months.
In September it acquired a patent for stent graft technology.
A month later the company cemented one of its largest deals to date, acquiring seven portfolios with more than 1,900 patents and applications, including some related to retrieval and vena cava filter technologies, among several others.
The licensing deal is thought to be with Natick, Mass.-based Boston Scientific Corp., though the company was unnamed in the announcement. Financial details are also uncertain, but Acacia typically splits sales, licensing fees and court settlements with the patent holders.
Acacia shares are down 2.1% in afternoon trading, with a market value of $1.19 billion.